Egalet, a small pharmaceutical company, has raised the list price of its pain reliever and anti-inflammatory drug, Zorvolex, by 70%. A 90-pill bottle of Zorvolex now has a price tag of $650, compared with $383 a year ago, according to Elsevier's Gold Standard Drug Database.

The big picture: The drug does not generate a lot of relative sales, but the move is indicative of the pricing power drug companies still have, especially when drugs change ownership. The 70% price hike went into effect Feb. 1 — the day after Egalet completed its acquisition of Iroko Pharmaceuticals, the company that had owned Zorvolex.

Details: Zorvolex's new list price, which was spotted by drug pricing data firm 46brooklyn Research, does not include rebates or discounts.

  • There is little data about sales of Zorvolex, a low-dose pain reliever that received FDA approval in 2013. Iroko canceled an initial public offering that year, before sales officially started.
  • Egalet agreed to acquire Iroko last year, and the resulting company is going through the bankruptcy protection process.
  • Egalet is pushing to increase the total revenue of its 6 drugs, including Zorvolex, to at least $80 million annually.
  • A new sales team "will target pain medicine physicians, primary care physicians, nurse practitioners, orthopedic surgeons and neurologists in the United States with the intent to build awareness and increase adoption of" its drugs, according to a bankruptcy proceeding plan.

The bottom line: Egalet significantly raised the price of a brand-name drug that has generic equivalents right after it bought the drug, and as it prepares to persuade doctors to prescribe more of the drug.

  • Egalet did not respond to multiple phone calls and emails.

Go deeper

Trump's new TikTok threat

Photo illustration: Aïda Amer/Axios. Photo: Jim Watson/AFP via Getty Images

President Trump said twice Monday that the U.S. Treasury would need to get a portion of the sale price of TikTok, as a condition of regulatory approval.

Why it matters: This is akin to extortion — the sort of thing you'd expect to hear on a wiretap, not from the White House in front of reporters.

Ford names James Farley as new CEO amid ongoing turnaround effort

James Hackett, left, is retiring as Ford CEO. Jim Farley, right, takes over Oct. 1. Photo: Ford

Ford announced Tuesday that James Farley will take over as its next CEO, replacing James Hackett, 65, who is retiring after three years in the job.

Why it matters: It leaves Farley to complete the company's ongoing turnaround effort. The transition will be that much harder as the industry tries to navigate the coronavirus-induced economic slowdown which shuttered Ford plants for two months on the eve of some of its most important vehicle launches.

Updated 3 hours ago - Politics & Policy

Watch the full "Axios on HBO" interview with President Trump

In this episode of “Axios on HBO”, President Trump discusses his handling of the coronavirus pandemic, the upcoming election and much more with National Political Correspondent Jonathan Swan.

The interview was filmed on Tuesday, July 28 and aired Monday, Aug. 3 on HBO.